TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22582765

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (I-CBT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 75
Study: 20101189

Group type: EXPERIMENTAL
Intervention: tesamorelin (2 mg SC every day)
Number of subjects: 404

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 404
Study: 17545008

Group type: EXPERIMENTAL
Intervention: Novel immunosuppressive agents and established immunosuppressive agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer immunosuppressive agents (proliferation signal inhibitors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Costimulatory pathway inhibitors and other new immunosuppressive agents
Number of subjects: 0
Study: 16213136

Group type: EXPERIMENTAL
Intervention: Intravaginal micronised progesterone 200 mg three times daily (n=351)
Number of subjects: 430

Group type: COMPARATOR
Intervention: Oral dydrogesterone 10 mg twice daily (n=79)
Number of subjects: 430
Study: 12360598

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 8 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 117
Study: 9952057

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 8536446

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 50 micrograms/norethindrone 1 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 35 micrograms/norethindrone 1 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 35 micrograms/norethindrone 0.5 mg
Number of subjects: 3
Study: 2029857

Group type: EXPERIMENTAL
Intervention: Cocaine abuse among heroin addicts
Number of subjects: 0
Study: 7348567

Group type: EXPERIMENTAL
Intervention: CMFH (CMF plus fluoxymesterone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 0
Study: 31679079

Group type: COMPARATOR
Intervention: Platelet aggregation in men with diabetes mellitus
Number of subjects: 720

Group type: COMPARATOR
Intervention: Coronary artery calcification (CAC) in men with diabetes mellitus
Number of subjects: 720
Study: 30973949

Group type: EXPERIMENTAL
Intervention: Severe maternal ACA
Number of subjects: 193
Study: 28027641

Group type: EXPERIMENTAL
Intervention: Wolfberry Extract (WBE) - 13.5 g in 80 mL pouch, consumed after one meal per day for 8 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 26604028

Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GMI)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Neural Mobilization (NM)
Number of subjects: 6
Study: 23570290

Group type: EXPERIMENTAL
Intervention: DSL v5 prescription
Number of subjects: 16

Group type: COMPARATOR
Intervention: NAL‐NL1 prescription
Number of subjects: 16
Study: 22122291

Group type: EXPERIMENTAL
Intervention: Children's appetite awareness training
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cue exposure treatment-food
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 36
Study: 19726540

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus streptozotocin (day 1-5)
Number of subjects: 64

Group type: COMPARATOR
Intervention: recombinant IFN-alpha-2a (3 MU x 3 per week)
Number of subjects: 64
Study: 17854593

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 18210717

Group type: EXPERIMENTAL
Intervention: Fixed drug combination RMP300 HIN150 (20 patients)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Single drug tablets (RMP and HIN) (18 patients)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups (20 patients with fixed drug combination and 18 patients with single drug tablets)
Number of subjects: 38
Study: 11483169

Group type: EXPERIMENTAL
Intervention: Spatial language tasks (naming tasks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial memory tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relationship between spatial language and spatial memory
Number of subjects: 0
Study: 9710018

Group type: EXPERIMENTAL
Intervention: MRI signal abnormalities on T2-weighted images (T2-WI)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MRI signal abnormalities on T1-weighted images (T1-WI)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Severity scores of hyperintensities
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Comparison of symptomatic vs asymptomatic gene carriers
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Presence of dementia or Rankin score > 1
Number of subjects: 75
Study: 7803946

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (specifics not detailed, but mentions diuretics and beta-adrenergic blocking drugs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antihypertensive treatment (ACE inhibitors and calcium channel blockers)
Number of subjects: 0
Study: 2468858

Group type: COMPARATOR
Intervention: Nifedipine 10 mg (acute oral administration)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg b.i.d. (chronic oral administration)
Number of subjects: 20
Study: 31790147

Group type: EXPERIMENTAL
Intervention: N-terminal B-type natriuretic peptide (NT-proBNP) screening and ECG recordings
Number of subjects: 6878

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 6878
Study: 29107569

Group type: EXPERIMENTAL
Intervention: School support intervention (school uniforms, tuition payment, nurse visits)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 835
Study: 28063325

Group type: EXPERIMENTAL
Intervention: In vivo NRT sampling (patch, gum, combination NRT)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: In vivo NRT sampling
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard smoking cessation with cNRT
Number of subjects: 43
Study: 25051390

Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg·kg of caffeine)
Number of subjects: 13
Study: 23541416

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (ganirelix 0.25mg daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Natural control cycle
Number of subjects: 35
Study: 20716145

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy, low dose (2.5/80 mg, titrated to 5/160 mg or 10/160 mg)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy, high dose (5/80 mg, titrated to 5/160 mg or 10/160 mg)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy with optional hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy, low dose
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy, high dose
Number of subjects: 1246
Study: 18156922

Group type: EXPERIMENTAL
Intervention: Intra-arterial iodine-131-labeled lipiodol (1850 MBq dose)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No adjuvant treatment (control)
Number of subjects: 43
Study: 15716559

Group type: EXPERIMENTAL
Intervention: Intrathecal analgesia
Number of subjects: 750

Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 750
Study: 12911824

Group type: EXPERIMENTAL
Intervention: Serrapeptase (SER) 30 mg/day for 4 weeks
Number of subjects: 29
Study: 10423656

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 0
Study: 8910932

Group type: EXPERIMENTAL
Intervention: LCP group (n = 13)
Number of subjects: 35

Group type: COMPARATOR
Intervention: NO‐LCP group (n = 15)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Human milk group (n = 7)
Number of subjects: 35
Study: 1879595

Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 7421183

Group type: EXPERIMENTAL
Intervention: Biofeedback-relaxation therapy (30 1-hour training sessions over a 13-week period)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Biofeedback-relaxation therapy (after 3 months of control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Biofeedback-relaxation therapy
Number of subjects: 11
Study: 31430226

Group type: EXPERIMENTAL
Intervention: Pyrotinib (400 mg orally once per day) combined with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Lapatinib (1,250 mg orally once per day) combined with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Pyrotinib
Number of subjects: 128
Study: 28489889

Group type: EXPERIMENTAL
Intervention: Ascaris lumbricoides infection
Number of subjects: 2194

Group type: EXPERIMENTAL
Intervention: Necator americanus infection
Number of subjects: 2194

Group type: EXPERIMENTAL
Intervention: Any STH infection
Number of subjects: 2194
Study: 26130342

Group type: EXPERIMENTAL
Intervention: Navigated 'femur-first' THA
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conventional THA
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study: 23448616

Group type: EXPERIMENTAL
Intervention: Ticagrelor (450 mg single dose, 180 mg 12 hours later, twice daily for 2 days, and once on day 4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21784734

Group type: EXPERIMENTAL
Intervention: E(2)V/DNG
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 19764168

Group type: EXPERIMENTAL
Intervention: Hollow earmold with vent diameters of 0, 1, 2, and 3 mm
Number of subjects: 8

Group type: COMPARATOR
Intervention: Solid earmold with vent diameters of 0, 1, 2, and 3 mm
Number of subjects: 8
Study: 17204037

Group type: EXPERIMENTAL
Intervention: BOD POD FRC measurement
Number of subjects: 92

Group type: COMPARATOR
Intervention: BOD POD FRC trial #1 measurement
Number of subjects: 92
Study: 15169685

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: NK(3) antagonist (SR142801)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: 5‐HT(2A/2C) antagonist (SR46349B)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: CB(1) antagonist (SR141716)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: NTS(1) antagonist (SR48692)
Number of subjects: 481
Study: 11821367

Group type: EXPERIMENTAL
Intervention: Nurse visits over 6 months with blood pressure checks and negotiated lifestyle changes
Number of subjects: 718

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Nurse visits
Number of subjects: 718
Study: 9723827

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Captopril (25 mg twice daily)
Number of subjects: 177
Study: 7979745

Group type: EXPERIMENTAL
Intervention: Lungs inflated during sternotomy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Lungs deflated during sternotomy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Sternotomy starting at the xiphoid
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sternotomy starting at the sternal notch
Number of subjects: 126
Study: 2566824

Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 220
Study: 1201184

Group type: EXPERIMENTAL
Intervention: Potassium supplements
Number of subjects: 8

Group type: COMPARATOR
Intervention: Prednisone (without potassium supplements)
Number of subjects: 8
Study: 30421547

Group type: EXPERIMENTAL
Intervention: Mindfulness-based interoceptive exposure task (MIET)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Distraction instructions
Number of subjects: 100

Group type: COMPARATOR
Intervention: No instructions (control group)
Number of subjects: 100
Study: 29072163

Group type: EXPERIMENTAL
Intervention: Low glycemic index breakfast
Number of subjects: 10

Group type: COMPARATOR
Intervention: High glycemic index breakfast
Number of subjects: 10
Study: 26149441

Group type: EXPERIMENTAL
Intervention: Kokoro-App plus switching antidepressant
Number of subjects: 164

Group type: COMPARATOR
Intervention: Switching antidepressant alone
Number of subjects: 164
Study: 23736998

Group type: EXPERIMENTAL
Intervention: Serum thymidine kinase 1 (TK1) activity
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: CA 15‐3
Number of subjects: 198
Study: 21275440

Group type: EXPERIMENTAL
Intervention: Trospium chloride 60 mg XR
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1135
Study: 19738015

Group type: EXPERIMENTAL
Intervention: Boost Plus 8 oz (240 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Boost Plus 4 oz (120 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Boost Plus 2 oz (60 ml)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Boost Plus 1 oz (30 ml)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fasting (no Boost Plus)
Number of subjects: 30
Study: 17803714

Group type: EXPERIMENTAL
Intervention: Misoprostol (600 micrograms oral)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 300
Study: 15167287

Group type: EXPERIMENTAL
Intervention: Atazanavir 400 mg
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Atazanavir 600 mg
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Nelfinavir-to-atazanavir switch (400 mg)
Number of subjects: 346

Group type: COMPARATOR
Intervention: Nelfinavir-to-atazanavir switch
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 346
Study: 11232658

Group type: EXPERIMENTAL
Intervention: Preoperative skin traction (5 pounds)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placement of a pillow under the injured extremity
Number of subjects: 100
Study: 9514180

Group type: EXPERIMENTAL
Intervention: Cicletanine (50 mg daily, orally)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7995312

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 102

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide added to Lisinopril
Number of subjects: 102

Group type: COMPARATOR
Intervention: Hydrochlorothiazide added to Nifedipine
Number of subjects: 102
Study: 2738780

Group type: EXPERIMENTAL
Intervention: Intermittent mandatory ventilation (n = 26)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (n = 27)
Number of subjects: 53
Study: 30309246

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring use
Number of subjects: 42
Study: 30135733

Group type: EXPERIMENTAL
Intervention: Supine position test for 3 minutes
Number of subjects: 76
Study: 26751191

Group type: EXPERIMENTAL
Intervention: NBI-77860 300 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NBI-77860 600 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 25499565

Group type: EXPERIMENTAL
Intervention: Real acupuncture at acupoint PC6
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonpenetrating sham acupuncture
Number of subjects: 33
Study: 22067277

Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Hormone Therapy (HT)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Not Treated (NT)
Number of subjects: 99
Study: 19293199

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 17616002

Group type: EXPERIMENTAL
Intervention: CCGC (combined capsaicin, green tea extract, and chicken essence tablets)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CCGC
Number of subjects: 6
Study: 16095444

Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (2% lidocaine, 15 ml, maintenance infusion rate of 6 ml h‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General anesthesia alone (normal saline, 15 ml, maintenance infusion rate of 6 ml h‐1)
Number of subjects: 30
Study: 11888096

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound assessment of bladder wall thickness
Number of subjects: 128

Group type: COMPARATOR
Intervention: Ambulatory urodynamics
Number of subjects: 128
Study: 9862538

Group type: EXPERIMENTAL
Intervention: Botulinus toxin Type A (400 mouse units injected into calf muscles)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Phenol (3 ml of 5% phenol via tibial nerve blockade)
Number of subjects: 20
Study: 7654129

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2576432

Group type: EXPERIMENTAL
Intervention: 0.5% D-timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% D-timolol (topical administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-timolol
Number of subjects: 0
Study: 27719741

Group type: COMPARATOR
Intervention: GSK2647544 (0.5 - 750 mg single escalating oral doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK2647544 (80 mg repeat doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GSK2647544 with simvastatin
Number of subjects: 0
Study: 31241048

Group type: EXPERIMENTAL
Intervention: FGG+I-PRF
Number of subjects: 40

Group type: COMPARATOR
Intervention: FGG
Number of subjects: 40
Study: 28501556

Group type: EXPERIMENTAL
Intervention: Contact - owner petting and talking to the dog during the examination
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-contact - owner present but not allowed to interact with the dog
Number of subjects: 33
Study: 27331240

Group type: EXPERIMENTAL
Intervention: Pilates-based intervention
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 17
Study: 23455596

Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg) with water
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg) with yoghurt-based drink
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg) with glucose-based drink
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Caffeine (80 mg) irrespective of vehicle
Number of subjects: 90
Study: 20848411

Group type: EXPERIMENTAL
Intervention: Provox Vega voice prosthesis
Number of subjects: 31
Study: 18434579

Group type: EXPERIMENTAL
Intervention: Dental amalgam restoration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mercury‐free composite resin restoration
Number of subjects: 0
Study: 16963034

Group type: EXPERIMENTAL
Intervention: Extended release metformin
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 626

Group type: COMPARATOR
Intervention: Baseline characterization
Number of subjects: 626
Study: 12937023

Group type: EXPERIMENTAL
Intervention: Glycogen-depleted state
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glycogen-loaded state
Number of subjects: 8
Study: 10939702

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen 400 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral dextromethorphan 120 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen 400 mg and dextromethorphan 120 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dextromethorphan alone
Number of subjects: 100
Study: 9184737

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (68% CHO)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal carbohydrate diet (45% CHO)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 19
Study: 1350481

Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol (100 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study: 4007027

Group type: EXPERIMENTAL
Intervention: Bay g 2821 (muzolimine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide-amiloride
Number of subjects: 0
Study: 29448219

Group type: EXPERIMENTAL
Intervention: Tall obstacle crossing
Number of subjects: 33

Group type: COMPARATOR
Intervention: Tall obstacle crossing in PD group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Long obstacle crossing in PD group
Number of subjects: 33
Study: 27663186

Group type: EXPERIMENTAL
Intervention: Symptom management (SM) drugs
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Disease management (DM) drugs
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Anticholinergic load (ACL)
Number of subjects: 244
Study: 23716270

Group type: EXPERIMENTAL
Intervention: Laboratory method (direct inspection under the light microscope)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Projection method (photomicrographs of glass slides with classroom projection)
Number of subjects: 41
Study: 23775187

Group type: EXPERIMENTAL
Intervention: Providing an interactive game during free play
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervision and organised activities during unstructured settings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured (physical education) and unstructured (recess, lunch, before and after school) periods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contextual characteristics of the school environment
Number of subjects: 0
Study: 19947861

Group type: EXPERIMENTAL
Intervention: Jamshidi 15G
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: BIG 15G
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: FAST1
Number of subjects: 87

Group type: COMPARATOR
Intervention: All devices (adults overall)
Number of subjects: 87

Group type: COMPARATOR
Intervention: All devices (children overall)
Number of subjects: 87

Group type: COMPARATOR
Intervention: All devices
Number of subjects: 87
Study: 18162083

Group type: EXPERIMENTAL
Intervention: IV esomeprazole 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: IV lansoprazole 30 mg
Number of subjects: 24